Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
124 hedge funds and large institutions have $343M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 14 closing their positions.
39,500% more call options, than puts
Call options by funds: $396K | Put options by funds: $1K
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
27% more capital invested
Capital invested by funds: $271M → $343M (+$72.1M)
8% more funds holding
Funds holding: 115 → 124 (+9)
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$12.1M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$11.2M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.79M |
| 4 |
Barclays
London,
United Kingdom
|
+$5.59M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$4.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.2M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$15.7M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.36M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.67M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.58M |
JNCE Hedge Fund Activity: Q4 2021 in Review
124 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2021, worth a combined $343M — up 27% from $271M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new JNCE positions and 14 closed out — a net gain of 9 holders — while 37 added to existing stakes and 36 trimmed.
The largest buyer was RTW Investments, adding an estimated $12.1M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $18.2M sold.
- 124 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2021, up from 115 in Q3 2021.
- Funds reported $343M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2021, up 27% quarter-over-quarter.
- 23 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2021 and 14 closed out, a net change of +9 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2021 was RTW Investments, an estimated $12.1M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2021 was Adage Capital Partners, an estimated $18.2M sold.
Based on aggregated 13F filings for Q4 2021.